What is Biogen's SPINRAZA — total revenue?

Biogen (BIIB) reported SPINRAZA — total revenue of $374M in Q1 2026.

How has Biogen's SPINRAZA — total revenue changed year-over-year?

Biogen's SPINRAZA — total revenue decreased by 11.8% year-over-year, from $423.9M to $374M.

What is the long-term trend for Biogen's SPINRAZA — total revenue?

Over 4 years (2021 to 2025), Biogen's SPINRAZA — total revenue has grown at a -5.1% compound annual growth rate (CAGR), from $1.91B to $1.55B.

What does SPINRAZA — total revenue mean?

Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic segment. This metric reflects the market demand and commercial performance of the product within the company's portfolio.

Biogen BIIB SPINRAZA — Total Revenue

Other product segments

TYSABRI

$441.5M+15.7%

VUMERITY

$179M+29.0%

AVONEX

$163.2M-2.2%

SKYCLARYS

$150.7M+21.6%

BENEPALI

$122.1M+9.7%

TECFIDERA

$109.5M-46.9%

PLEGRIDY

$64.3M+8.1%

ZURZUVAE

$55.4M+100%

IMRALDI

$49.6M+4.6%

QALSODY

$32.5M+110%

FLIXABI

$10.5M-19.8%

BYOOVIZ

$0-100%

FAMPYRA

$0-100%

FUMADERM And ADUHELM

$0-100%

TOFIDENCE

$0-100%

Similar metrics at other companies

IONSSpinraza Royalties — Revenue

$43.71M-9.0%

AMGNTEZSPIRE — Total revenues

$343M+20.4%

TVTXFILSPARI — Total Revenue

$105.15M+88.2%

IONSSpinraza — Maximum Amount Of Annual Sales On Which Royalty Payments Are Paid

$1.5B0.0%

JNJSPRAVATO — Sales to customers (Note 9)

$468M+46.3%

IONSSpinraza — Percentage Of Royalty Payments Paid On Annual Sales Of Medicine

45%0.0pp

Other financials

Income statement

See full

Revenue$2.5B+1.9%

Gross profit$1.8B+0.8%

Operating income$610.7M—

Net income$319.5M+32.8%

EPS (diluted)$2.15+31.1%

Balance sheet

See full

Cash & equivalents$3.4B+30.2%

Total debt$6.6B+34.7%

Total equity$18.7B+9.9%

Total assets$29.5B+5.2%

Cash flow

See full

Operating cash flow$645.5M+149%

CapEx$51.2M+38.0%

Free cash flow$594.3M+167%

Valuation

See full

Market cap$31.89B+72.3%

Enterprise value$35.07B+57.0%

P/E22.5×+10.4×

P/S3.2×+1.4×

Profitability

See full

Gross margin75.5%-0.1pp

Operating margin22.9%—

Net margin14.3%-0.8pp

FCF margin24.4%-0.4pp

Returns & leverage

See full

Return on equity8%-1.2pp

Debt / equity0.4×+0.1×

Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's spinraza — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's SPINRAZA — total revenue?: Biogen (BIIB) reported SPINRAZA — total revenue of $374M in Q1 2026.
How has Biogen's SPINRAZA — total revenue changed year-over-year?: Biogen's SPINRAZA — total revenue decreased by 11.8% year-over-year, from $423.9M to $374M.
What is the long-term trend for Biogen's SPINRAZA — total revenue?: Over 4 years (2021 to 2025), Biogen's SPINRAZA — total revenue has grown at a -5.1% compound annual growth rate (CAGR), from $1.91B to $1.55B.
What does SPINRAZA — total revenue mean?: Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic segment. This metric reflects the market demand and commercial performance of the product within the company's portfolio.